Matching articles for "risperidone"
Issue 1746 · January 19, 2026 Free
In Brief: A New Indication for Uzedy

Uzedy , an extended-release, subcutaneous (SC) formulation of the second-generation antipsychotic drug risperidone, was approved by the FDA in 2023 for treatment of schizophrenia in adults. It has now been…

Med Lett Drugs Ther. 2026 Jan 19; 68(1746):15-6 doi:10.58347/tml.2026.1746e
Uzedy , an extended-release, subcutaneous (SC) formulation of the second-generation antipsychotic drug risperidone, was approved by the FDA in 2023 for treatment of schizophrenia in adults. It has now been approved for use as monotherapy or in combination with lithium or valproate for maintenance treatment of bipolar I disorder in adults. Extended-release, intramuscular (IM) formulations of risperidone ( Risperdal Consta and Rykindo ) are also approved for treatment of bipolar I disorder (see Table 1).
Issue 1707 · July 22, 2024
Iloperidone (Fanapt) — A New Indication for Bipolar Disorder

The oral second-generation antipsychotic drug iloperidone ( Fanapt – Vanda) has been approved by the FDA for acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. First…

Med Lett Drugs Ther. 2024 Jul 22; 66(1707):115-6 doi:10.58347/tml.2024.1707c
The oral second-generation antipsychotic drug iloperidone ( Fanapt – Vanda) has been approved by the FDA for acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. First approved in 2009 for treatment of schizophrenia, iloperidone is the eighth second-generation antipsychotic to be approved for acute treatment of manic or mixed episodes of bipolar I disorder (see Table 1).
Issue 1699 · April 1, 2024
Drugs for Bipolar Disorder

Bipolar disorder is characterized by episodes of mania, hypomania, and depression. Recurrences of manic or (more frequently) depressive symptoms are common. About 15-20% of patients with bipolar disorder die…

Med Lett Drugs Ther. 2024 Apr 1; 66(1699):49-54 doi:10.58347/tml.2024.1699a
Bipolar disorder is characterized by episodes of mania, hypomania, and depression. Recurrences of manic or (more frequently) depressive symptoms are common. About 15-20% of patients with bipolar disorder die by suicide.
Issue 1699 · April 1, 2024
Drugs for Bipolar Disorder

Bipolar disorder is characterized by episodes of mania, hypomania, and depression. Recurrences of manic or (more frequently) depressive symptoms are common. About 15-20% of patients with bipolar disorder die…

Med Lett Drugs Ther. 2024 Apr 1; 66(1699):49-54 doi:10.58347/tml.2024.1699a
Bipolar disorder is characterized by episodes of mania, hypomania, and depression. Recurrences of manic or (more frequently) depressive symptoms are common. About 15-20% of patients with bipolar disorder die by suicide.
Issue 1692 · December 25, 2023 Free
In Brief: Three New Injectable Antipsychotic Drugs

Three extended-release injectable formulations of second-generation antipsychotic drugs — two of risperidone (Rykindo, Uzedy) and one of aripiprazole (Abilify Asimtufii) — have been approved by the FDA for…

Med Lett Drugs Ther. 2023 Dec 25; 65(1692):207-8 doi:10.58347/tml.2023.1692d
Three extended-release injectable formulations of second-generation antipsychotic drugs — two of risperidone (Rykindo, Uzedy) and one of aripiprazole (Abilify Asimtufii) — have been approved by the FDA for treatment of schizophrenia in adults. Rykindo and Abilify Asimtufii are also approved for maintenance treatment of bipolar I disorder in adults. Other extended-release injectable formulations of risperidone and aripiprazole have been available in the US for years (see Table 1).
Issue 1666 · December 26, 2022
Dexmedetomidine Sublingual Film (Igalmi) for Acute Agitation

The FDA has approved a sublingual film formulation of the alpha-2 adrenergic receptor agonist dexmedetomidine ( Igalmi — BioXcel Therapeutics) for acute treatment of agitation associated with schizophrenia…

Med Lett Drugs Ther. 2022 Dec 26; 64(1666):203-5
The FDA has approved a sublingual film formulation of the alpha-2 adrenergic receptor agonist dexmedetomidine ( Igalmi — BioXcel Therapeutics) for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It is the first alpha-2 agonist and the only sublingual film to be approved for this indication. Dexmedetomidine has been available for many years in an injectable formulation (Precedex) for sedation in the intensive care unit and to facilitate procedures such as mechanical ventilation.
Issue 1641 · January 10, 2022 Free
In Brief: Twice-Yearly Paliperidone (Invega Hafyera) for Schizophrenia

Invega Hafyera (Janssen), a long-acting, extended-release (ER) formulation of the second-generation antipsychotic paliperidone palmitate, has been approved by the FDA for twice-yearly IM treatment of…

Med Lett Drugs Ther. 2022 Jan 10; 64(1641):7-8
Invega Hafyera (Janssen), a long-acting, extended-release (ER) formulation of the second-generation antipsychotic paliperidone palmitate, has been approved by the FDA for twice-yearly IM treatment of schizophrenia in adults who have been adequately treated with another injectable ER formulation of the drug ( Invega Sustenna or Invega Trinza ). It is the first drug to become available in the US for twice-yearly treatment of schizophrenia.
Issue 1603 · July 27, 2020
Lumateperone (Caplyta) for Schizophrenia

The FDA has approved lumateperone ( Caplyta — Intracellular Therapies), an oral second-generation antipsychotic, for once-daily treatment of schizophrenia in adults. It is the 13th second-generation…

Med Lett Drugs Ther. 2020 Jul 27; 62(1603):113-6
The FDA has approved lumateperone ( Caplyta — Intracellular Therapies), an oral second-generation antipsychotic, for once-daily treatment of schizophrenia in adults. It is the 13th second-generation antipsychotic drug to be approved by the FDA for this indication.
Issue 1530 · September 25, 2017
Drugs for Cognitive Loss and Dementia

Alzheimer's disease (AD) is the most common cause of dementia, but cognitive loss is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, vascular…

Med Lett Drugs Ther. 2017 Sep 25; 59(1530):155-61
Alzheimer's disease (AD) is the most common cause of dementia, but cognitive loss is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, vascular dementia, and frontotemporal dementia.
Issue 1510 · December 19, 2016
Drugs for Psychotic Disorders

Oral antipsychotic drugs used for treatment of schizophrenia, schizoaffective disorder, delusional disorder, and other manifestations of psychosis or mania are listed in Table 1. Parenteral antipsychotic drugs…

Med Lett Drugs Ther. 2016 Dec 19; 58(1510):160-4
Oral antipsychotic drugs used for treatment of schizophrenia, schizoaffective disorder, delusional disorder, and other manifestations of psychosis or mania are listed in Table 1. Parenteral antipsychotic drugs used for treatment of these disorders are listed in Table 2.
Issue 1501 · August 15, 2016
Drugs for Bipolar Disorder

Bipolar disorder is characterized by intermittent episodes of mania and/or depression. Even with maintenance treatment, recurrences of manic or (more frequently) depressive episodes are common. Some of the…

Med Lett Drugs Ther. 2016 Aug 15; 58(1501):103-6
Bipolar disorder is characterized by intermittent episodes of mania and/or depression. Even with maintenance treatment, recurrences of manic or (more frequently) depressive episodes are common. Some of the drugs and dosages recommended here have not been approved by the FDA for use in bipolar disorder.
Issue 1493 · April 25, 2016
Cariprazine (Vraylar) for Schizophrenia and Bipolar I Disorder

The FDA has approved cariprazine ( Vraylar – Actavis), an oral, once-daily, second-generation antipsychotic, for treatment of schizophrenia and for acute treatment of manic or mixed episodes associated with…

Med Lett Drugs Ther. 2016 Apr 25; 58(1493):51-3
The FDA has approved cariprazine ( Vraylar – Actavis), an oral, once-daily, second-generation antipsychotic, for treatment of schizophrenia and for acute treatment of manic or mixed episodes associated with bipolar I disorder.
Issue 1481 · November 9, 2015
Two Long-Acting Injectable Antipsychotics for Schizophrenia

The FDA has approved two new long-acting injectable formulations of second-generation antipsychotics for treatment of schizophrenia: aripiprazole lauroxil ( Aristada – Alkermes), which is given once every…

Med Lett Drugs Ther. 2015 Nov 9; 57(1481):152-3
The FDA has approved two new long-acting injectable formulations of second-generation antipsychotics for treatment of schizophrenia: aripiprazole lauroxil ( Aristada – Alkermes), which is given once every 4-6 weeks, and paliperidone palmitate ( Invega Trinza – Janssen), which is given once every 3 months. Once-monthly injectable formulations of aripiprazole (Abilify Maintena) and paliperidone palmitate (Invega Sustenna) were approved earlier.
Issue 1475 · August 17, 2015
Brexpiprazole (Rexulti) for Schizophrenia and Depression

The FDA has approved the oral, once-daily, second-generation antipsychotic brexpiprazole ( Rexulti – Otsuka/Lundbeck) for treatment of schizophrenia and as an adjunct to antidepressants for treatment of…

Med Lett Drugs Ther. 2015 Aug 17; 57(1475):116-8
The FDA has approved the oral, once-daily, second-generation antipsychotic brexpiprazole ( Rexulti – Otsuka/Lundbeck) for treatment of schizophrenia and as an adjunct to antidepressants for treatment of major depressive disorder (MDD). Aripiprazole (Abilify) , a structurally similar second-generation antipsychotic also comarketed by Otsuka (with BMS), recently became available generically.
Issue 134 · October 1, 2013
Drugs for Cognitive Loss and Dementia

Alzheimer's disease (AD) is the most common cause of dementia, but cognitive loss is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, and vascular…

Treat Guidel Med Lett. 2013 Oct; 11(134):95-100
Alzheimer's disease (AD) is the most common cause of dementia, but cognitive loss is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, and vascular dementia. Mild cognitive impairment (MCI) is generally defined as cognitive decline greater than expected for an individual's age and educational level, but not interfering with activities of daily living; it may be a transitional state between the cognitive changes of normal aging and dementia.
Issue 130 · June 1, 2013
Drugs for Psychiatric Disorders

Drugs are not the only treatment for psychiatric illness. Psychotherapy remains an important component in the management of these disorders, and cognitive behavioral therapy (CBT) can be used for many of them…

Treat Guidel Med Lett. 2013 Jun; 11(130):53-64
Drugs are not the only treatment for psychiatric illness. Psychotherapy remains an important component in the management of these disorders, and cognitive behavioral therapy (CBT) can be used for many of them as well. Electroconvulsive therapy (ECT) has a long history of efficacy and safety when drugs are ineffective or cannot be used.
Issue 1415 · April 29, 2013
Long-Acting Injectable Aripiprazole (Abilify Maintena) for Schizophrenia

An extended-release injectable formulation of the second-generation antipsychotic aripiprazole (Abilify) has been approved by the FDA ( Abilify Maintena – Otsuka/Lundbeck) for once-monthly treatment of…

Med Lett Drugs Ther. 2013 Apr 29; 55(1415):34-6
An extended-release injectable formulation of the second-generation antipsychotic aripiprazole (Abilify) has been approved by the FDA ( Abilify Maintena – Otsuka/Lundbeck) for once-monthly treatment of schizophrenia. It is the fourth second-generation antipsychotic to become available in a long-acting parenteral formulation. Long-acting parenteral antipsychotics, given at intervals of 2-4 weeks, are generally used for patients with a history of relapse due to poor adherence to oral maintenance therapy.
Issue 1373 · September 19, 2011
Adjunctive Antipsychotics for Major Depression

Augmentation with a second-generation (atypical) antipsychotic is a treatment option for patients with major depressive disorder (MDD) whose symptoms persist following antidepressant monotherapy. Aripiprazole…

Med Lett Drugs Ther. 2011 Sep 19; 53(1373):74-5
Augmentation with a second-generation (atypical) antipsychotic is a treatment option for patients with major depressive disorder (MDD) whose symptoms persist following antidepressant monotherapy. Aripiprazole (Abilify) , olanzapine in a fixed-dose combination with fluoxetine (Symbyax) , and extended-release quetiapine (Seroquel XR) have been approved by the FDA for such use.
Issue 1358 · February 21, 2011
Lurasidone (Latuda) for Schizophrenia

The FDA has approved lurasidone ( Latuda - Sunovion), a new second-generation antipsychotic, for oral treatment of schizophrenia in adults.

Med Lett Drugs Ther. 2011 Feb 21; 53(1358):13-4
The FDA has approved lurasidone ( Latuda - Sunovion), a new second-generation antipsychotic, for oral treatment of schizophrenia in adults.
Issue 96 · August 1, 2010
Drugs for Psychotic Disorders

The antipsychotic drugs listed in Table 1 on the next page are more effective for treating the “positive symptoms” of schizophrenia (hallucinations and delusions) than the “negative symptoms” (apathy,…

Treat Guidel Med Lett. 2010 Aug; 8(96):61-4
The antipsychotic drugs listed in Table 1 on the next page are more effective for treating the “positive symptoms” of schizophrenia (hallucinations and delusions) than the “negative symptoms” (apathy, social withdrawal, and blunted affect). Some symptoms of schizophrenia and acute psychoses may improve rapidly after treatment with antipsychotic drugs, but chronic schizophrenia improves slowly over many weeks and some patients may continue to improve for months. Most patients with chronic schizophrenia require prolonged maintenance therapy, but the risk of tardive dyskinesia and adverse metabolic effects must be kept in mind.
Issue 93 · May 1, 2010
Drugs for Depression and Bipolar Disorder

Drugs are not the only treatment for mood disorders. Psychotherapy remains an important component in the management of these disorders, and electroconvulsive therapy (ECT) has a long history of efficacy and…

Treat Guidel Med Lett. 2010 May; 8(93):35-42
Drugs are not the only treatment for mood disorders. Psychotherapy remains an important component in the management of these disorders, and electroconvulsive therapy (ECT) has a long history of efficacy and safety when drugs are ineffective, poorly tolerated or cannot be used. Some drugs are recommended here for indications that have not been approved by the FDA.
Issue 1332 · February 22, 2010
Iloperidone (Fanapt) - Another Second-Generation Antipsychotic

The FDA has approved the marketing of iloperidone ( Fanapt – Vanda), a second-generation antipsychotic, for treatment of schizophrenia. Iloperidone is chemically related to risperidone ( Risperdal , and…

Med Lett Drugs Ther. 2010 Feb 22; 52(1332):13-4
The FDA has approved the marketing of iloperidone ( Fanapt – Vanda), a second-generation antipsychotic, for treatment of schizophrenia. Iloperidone is chemically related to risperidone ( Risperdal , and others).
Issue 1331 · February 8, 2010
Asenapine (Saphris) Sublingual Tablets for Schizophrenia and Bipolar Disorder

Asenapine ( Saphris - Schering-Plough), a dibenzo-oxepino pyrrole, has been approved by the FDA in a sublingual tablet formulation for acute treatment of schizophrenia and manic or mixed episodes associated…

Med Lett Drugs Ther. 2010 Feb 8; 52(1331):9-10
Asenapine ( Saphris - Schering-Plough), a dibenzo-oxepino pyrrole, has been approved by the FDA in a sublingual tablet formulation for acute treatment of schizophrenia and manic or mixed episodes associated with bipolar disorder. It is the sixth second-generation antipsychotic approved by the FDA for use in bipolar disorder.
Issue 1324 · November 2, 2009 Free
In Brief: Injectable Paliperidone Palmitate for Schizophrenia

Paliperidone palmitate ( Invega Sustenna – Ortho-McNeil Janssen) has been approved by the FDA as a once-monthly injection for acute and maintenance treatment of schizophrenia in adults. An extended-release…

Med Lett Drugs Ther. 2009 Nov 2; 51(1324):88
Paliperidone palmitate ( Invega Sustenna – Ortho-McNeil Janssen) has been approved by the FDA as a once-monthly injection for acute and maintenance treatment of schizophrenia in adults. An extended-release oral formulation (Invega) has been available since 2006. 1 Long-acting injections of antipsychotic drugs typically are used to treat patients who cannot adhere to an oral regimen. 2,3 Paliperidone is the primary active metabolite of risperidone (Risperdal) , which is also available as a long-acting (every 2 weeks) injection. It is unclear whether either risperidone or paliperidone is a better choice for long-term treatment of schizophrenia than a first-generation drug such as haloperidol, which can also be injected once a month and costs much less. 4 1. Paliperidone (Invega) for schizophrenia. Med Lett Drugs Ther 2007; 49:21. 2. JC West et al. Use of depot antipsychotic medications for medication non-adherence in schizophrenia. Schizophr Bull 2008; 34:995. 3. D Hough et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:1022. 4. Drugs for psychiatric disorders. Treat Guidel Med Lett 2006; 4:35. Download: U.S. English
Issue 1318 · August 10, 2009
Tablet Splitting

Readers have asked us to update our 2004 article on tablet splitting. Breaking drug tablets in half is a common practice, but the FDA recently advised consumers against it (FDA Consumer Health Information,…

Med Lett Drugs Ther. 2009 Aug 10; 51(1318):62-3
Readers have asked us to update our 2004 article on tablet splitting. Breaking drug tablets in half is a common practice, but the FDA recently advised consumers against it (FDA Consumer Health Information, July 2009).
Issue 1304 · January 26, 2009
Tetrabenazine (Xenazine) for Huntington's Chorea

Tetrabenazine ( Xenazine - Ovation Pharmaceuticals), an old drug first synthesized 50 years ago for treatment of schizophrenia, was recently approved by the FDA for the treatment of chorea associated with…

Med Lett Drugs Ther. 2009 Jan 26; 51(1304):7-8
Tetrabenazine ( Xenazine - Ovation Pharmaceuticals), an old drug first synthesized 50 years ago for treatment of schizophrenia, was recently approved by the FDA for the treatment of chorea associated with Huntington's disease. It has been available in other countries for decades.
Issue 1256 · March 12, 2007
Paliperidone (Invega) for Schizophrenia

Paliperidone ( Invega - Janssen) has been approved by the FDA in an extended-release formulation for treatment of schizophrenia. It is the primary active metabolite of the second-generation antipsychotic…

Med Lett Drugs Ther. 2007 Mar 12; 49(1256):21-3
Paliperidone ( Invega - Janssen) has been approved by the FDA in an extended-release formulation for treatment of schizophrenia. It is the primary active metabolite of the second-generation antipsychotic risperidone ( Risperdal - Janssen), which is scheduled to lose its patent exclusivity in December 2007.
Issue 46 · June 1, 2006
Drugs for Psychiatric Disorders

Drugs are not the only treatment for psychiatric illness. Psychotherapy remains an important component in the management of these disorders, and cognitive behavioral therapy (CBT) is used for many of them as…

Treat Guidel Med Lett. 2006 Jun; 4(46):35-46
Drugs are not the only treatment for psychiatric illness. Psychotherapy remains an important component in the management of these disorders, and cognitive behavioral therapy (CBT) is used for many of them as well. Electroconvulsive therapy (ECT) has a long history of efficacy and safety when drugs are ineffective or cannot be used.
Issue 1219 · October 10, 2005
Second-Generation Antipsychotics - Aripiprazole Revisited

Aripiprazole ( Abilify - Bristol-Myers Squibb/Otsuka), a second-generation (atypical) antipsychotic drug, was approved by the FDA in 2002 for treatment of schizophrenia and more recently for bipolar disorder…

Med Lett Drugs Ther. 2005 Oct 10; 47(1219):81-2
Aripiprazole ( Abilify - Bristol-Myers Squibb/Otsuka), a second-generation (atypical) antipsychotic drug, was approved by the FDA in 2002 for treatment of schizophrenia and more recently for bipolar disorder as well. It has been promoted as causing fewer adverse effects than other antipsychotics, without sacrificing efficacy.
Issue 1215 · August 15, 2005
AmpliChip CYP450 Test

The FDA recently cleared the AmpliChip CYP450 Test (Roche), which analyzes blood-derived DNA to detect genetic variations in the activity of cytochrome P450 (CYP) enzymes CYP2D6 and CYP2C19 and determines the…

Med Lett Drugs Ther. 2005 Aug 15; 47(1215):71-2
The FDA recently cleared the AmpliChip CYP450 Test (Roche), which analyzes blood-derived DNA to detect genetic variations in the activity of cytochrome P450 (CYP) enzymes CYP2D6 and CYP2C19 and determines the metabolizer status of the patient. The test is intended to help guide clinicians in prescribing individualized drug therapy. About 25% of all drugs, including many antidepressants and antipsychotics, are substrates of either CYP2D6 or CYP2C19. The test is being promoted initially to psychiatrists.
Issue 1214 · August 1, 2005
Atypical Antipsychotics in the Elderly

The FDA has reported that 5106 elderly patients with dementia treated with atypical (second generation) antipsychotics in 17 randomized controlled trials had a higher mortality rate (4.5% vs. 2.6%) than those…

Med Lett Drugs Ther. 2005 Aug 1; 47(1214):61-2
The FDA has reported that 5106 elderly patients with dementia treated with atypical (second generation) antipsychotics in 17 randomized controlled trials had a higher mortality rate (4.5% vs. 2.6%) than those receiving placebo. Most of the deaths were due to cardiovascular and infectious causes (such as pneumonia). The drugs used in the trials were aripiprazole (Abilify) , olanzapine (Zyprexa) , quetiapine (Seroquel) , and risperidone (Risperdal) . As the increase in mortality was considered a class effect, the FDA advisory also included ziprasidone (Geodon) , clozapine (Clozaril) and the olanzapine/fluoxetine combination (Symbyax) . The manufacturers of all of these drugs will be required to add a "black box" warning to their labeling.
Issue 1205 · March 28, 2005
Extended-Release Carbamazepine (Equetro) for Bipolar Disorder

An extended-release formulation of carbamazepine, available since 1997 for treatment of epilepsy, has now been approved under a new name, Equetro , for acute mania and mixed episodes of bipolar disorder.…

Med Lett Drugs Ther. 2005 Mar 28; 47(1205):27-8
An extended-release formulation of carbamazepine, available since 1997 for treatment of epilepsy, has now been approved under a new name, Equetro , for acute mania and mixed episodes of bipolar disorder. Although the drug was effective in some patients for up to 6 months, it has not been approved for maintenance treatment. Carbamazepine has not been shown to be more effective than lithium or valproate, and it can cause serious adverse effects.
Issue 1172 · December 22, 2003
Choice of an Antipsychotic

A recent supplement to the Journal of Clinical Psychiatry , titled "The Expert Consensus Guideline Series: Optimizing Pharmacologic Treatment of Psychotic Disorders," concluded that most experts endorsed use…

Med Lett Drugs Ther. 2003 Dec 22; 45(1172):102-4
A recent supplement to the Journal of Clinical Psychiatry , titled "The Expert Consensus Guideline Series: Optimizing Pharmacologic Treatment of Psychotic Disorders," concluded that most experts endorsed use of second-generation (atypical) antipsychotics rather than first-generation drugs, with risperidone ( Risperdal - Janssen) the top choice for first episodes, multiple episodes or switches from another drug (JM Kane et al, J Clin Psychiatry 2003; 64 suppl 12:5). The supplement was sponsored by Janssen.
Issue 11 · July 1, 2003
Drugs for Psychiatric Disorders

The number of drugs marketed for psychiatric indications has increased sharply in recent years. The recommendations in this article are based on the results of controlled trials and on the experience and…

Treat Guidel Med Lett. 2003 Jul; 1(11):69-76
The number of drugs marketed for psychiatric indications has increased sharply in recent years. The recommendations in this article are based on the results of controlled trials and on the experience and opinions of Medical Letter consultants. Interactions with other drugs can be found in The Medical Letter Handbook of Adverse Drug Interactions, 2003 .
Issue 1158 · June 8, 2003
Drug Interactions

Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug…

Med Lett Drugs Ther. 2003 Jun 8; 45(1158):46-8
Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.
Issue 1150 · February 17, 2003
Aripiprazole (Abilify) for Schizophrenia

Aripiprazole ( Abilify - Bristol-Myers Squibb/Otsuka), a quinolinone derivative, has been approved by the FDA for treatment of schizophrenia.

Med Lett Drugs Ther. 2003 Feb 17; 45(1150):15-6
Aripiprazole ( Abilify - Bristol-Myers Squibb/Otsuka), a quinolinone derivative, has been approved by the FDA for treatment of schizophrenia.
Issue 1106 · June 11, 2001
Ziprasidone (Geodon) For Schizophrenia

Ziprasidone ( Geodon - Pfizer), a benzisothiazolyl piperazine, has been approved by the FDA for oral treatment of schizophrenia. An intramuscular formulation will probably be available in the near future.

Med Lett Drugs Ther. 2001 Jun 11; 43(1106):51-2
Ziprasidone ( Geodon - Pfizer), a benzisothiazolyl piperazine, has been approved by the FDA for oral treatment of schizophrenia. An intramuscular formulation will probably be available in the near future.
Issue 1016 · December 19, 1997
Quetiapine for Schizophrenia

Quetiapine ( Seroquel - Zeneca), a dibenzothiazepine derivative, has been approved by the FDA for treatment of schizophrenia and other psychotic disorders. It is a new addition to the 'atypical'…

Med Lett Drugs Ther. 1997 Dec 19; 39(1016):117-8
Quetiapine ( Seroquel - Zeneca), a dibenzothiazepine derivative, has been approved by the FDA for treatment of schizophrenia and other psychotic disorders. It is a new addition to the 'atypical' antipsychotics, which include olanzapine ( Zyprexa - Medical Letter, 39:5, 1997), risperidone ( Risperdal ) and clozapine ( Clozaril ). Atypical antipsychotic drugs generally are less likely to cause extrapyramidal symptoms than older drugs such as haloperidol ( Haldol , and others) or the phenothiazines.
Issue 992 · January 19, 1997
Olanzapine for Schizophrenia

Olanzapine ( Zyprexa - Lilly), a thienobenzodiazepine that structurally resembles and binds to many of the same receptors as clozapine ( Clozaril ), is now available in the USA for treatment of schizophrenia…

Med Lett Drugs Ther. 1997 Jan 19; 39(992):5-6
Olanzapine ( Zyprexa - Lilly), a thienobenzodiazepine that structurally resembles and binds to many of the same receptors as clozapine ( Clozaril ), is now available in the USA for treatment of schizophrenia and other psychotic disorders.